BioSpace News Archive

Policy

Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange

Intellipharmaceutics International Inc. announces that, it has applied and received conditional approval to list the Company’s common shares for trading on the TSX Venture Exchange as a Tier 2 Life Science Issuer.

January 2, 2024
·
4 min read
Drug Development

Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China

Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic diseases, today announced positive topline results from a Phase 3 clinical trial of ecnoglutide (XW003) in Chinese adults with type 2 diabetes mellitus (T2DM).

January 2, 2024
·
4 min read
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th

Zealand Pharma A/S announced that President and Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference at 10:10 a.m. ET on Thursday, January 4, 2024.

January 2, 2024
·
1 min read
Deals

Calibre Scientific Acquires LineaLAB

Calibre Scientific has acquired LineaLAB, SL, a provider of analytical, bio and laboratory equipment based in Badalona.

January 2, 2024
·
4 min read
Policy

Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout

ABP-745 is an oral small molecule drug that also has potential applicationsfor other anti-inflammatory diseases

January 2, 2024
·
2 min read
Drug Development

Diakonos Oncology Completes Phase 1 Glioblastoma Trial Recruitment; Receives FDA Orphan Drug Designation

Diakonos Oncology Corporation, a clinical stage immuno-oncology company, announced it has completed enrollment for its Phase 1 trial of DOC1021, a unique dendritic cell vaccine, for Glioblastoma Multiforme.

January 2, 2024
·
2 min read
Lone Star Bio

Caris Life Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Caris Life Sciences announced today that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is being held January 8-11, 2024 in San Francisco.

January 2, 2024
·
2 min read
Genetown

Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 9:45 a.m. PT.

January 2, 2024
·
1 min read
Deals

NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard

NRx Pharmaceuticals, Inc. today announced an update on plans to achieve compliance with Nasdaq market requirements related to minimum bid price and total Market Value of Listed Securities (MVLS).

January 2, 2024
·
4 min read
Business

Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

Voyager Therapeutics, Inc. today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA).

January 2, 2024
·
7 min read